CLINICAL TRIAL

Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-03-16
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Johns Hopkins University

Watch author

Derived topics and classifications

psilocybin Depression Receptor Pharmacology Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07 Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14 TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-08-12 TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-08-12 Effects of Psilocybin in Patients With Amyotrophic Lateral SclerosisClinicalTrials.gov · 2026-08-11 Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10 Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-11-01